The Experts below are selected from a list of 357 Experts worldwide ranked by ideXlab platform
Eleftherios Mylonakis - One of the best experts on this subject based on the ideXlab platform.
-
Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori
Nature Publishing Group, 2018Co-Authors: Nagendra Tharmalingam, Dawilme Castillo, Eleftherios MylonakisAbstract:Abstract There is an urgent need to discover novel antimicrobial therapies. Drug repurposing can reduce the time and cost risk associated with drug development. We report the inhibitory effects of anthelmintic drugs (niclosamide, Oxyclozanide, closantel, rafoxanide) against Helicobacter pylori strain 60190 and pursued further characterization of niclosamide against H. pylori. The MIC of niclosamide against H. pylori was 0.25 μg/mL. Niclosamide was stable in acidic pH and demonstrated partial synergy with metronidazole and proton pump inhibitors, such as omeprazole and pantoprazole. Niclosamide administration at 1 × MIC concentration, eliminated 3-log10 CFU of H. pylori adhesion/invasion to AGS cells. Interestingly, no resistance developed even after exposure of H. pylori bacteria to niclosamide for 30 days. The cytotoxic assay demonstrated that niclosamide is not hemolytic and has an IC50 of 4 μg/mL in hepatic and gastric cell lines. Niclosamide administration decreased transmembrane pH as determined by DiSC3(5) assay indicating that the mechanism of action of the anti-H. pylori activity of niclosamide was the disruption of H. pylori proton motive force. Niclosamide was effective in the Galleria mellonella-H. pylori infection model (p = 0.0001) and it can be develop further to combat H. pylori infection. However, results need to be confirmed with other H. pylori and clinical strains
-
repurposing salicylanilide anthelmintic drugs to combat drug resistant staphylococcus aureus
PLOS ONE, 2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Eleftherios MylonakisAbstract:Staphylococcus aureus is a Gram-positive bacterium that has become the leading cause of hospital acquired infections in the US. Repurposing Food and Drug Administration (FDA) approved drugs for antimicrobial therapy involves lower risks and costs compared to de novo development of novel antimicrobial agents. In this study, we examined the antimicrobial properties of two commercially available anthelmintic drugs. The FDA approved drug niclosamide and the veterinary drug Oxyclozanide displayed strong in vivo and in vitro activity against methicillin resistant S. aureus (minimum inhibitory concentration (MIC): 0.125 and 0.5 μg/ml respectively; minimum effective concentration: ≤ 0.78 μg/ml for both drugs). The two drugs were also effective against another Gram-positive bacteria Enterococcus faecium (MIC 0.25 and 2 μg/ml respectively), but not against the Gram-negative species Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter aerogenes. The in vitro antimicrobial activity of niclosamide and Oxyclozanide were determined against methicillin, vancomycin, linezolid or daptomycin resistant S. aureus clinical isolates, with MICs at 0.0625-0.5 and 0.125-2 μg/ml for niclosamide and Oxyclozanide respectively. A time-kill study demonstrated that niclosamide is bacteriostatic, whereas Oxyclozanide is bactericidal. Interestingly, Oxyclozanide permeabilized the bacterial membrane but neither of the anthelmintic drugs exhibited demonstrable toxicity to sheep erythrocytes. Oxyclozanide was non-toxic to HepG2 human liver carcinoma cells within the range of its in vitro MICs but niclosamide displayed toxicity even at low concentrations. These data show that the salicylanilide anthelmintic drugs niclosamide and Oxyclozanide are suitable candidates for mechanism of action studies and further clinical evaluation for treatment of staphylococcal infections.
-
Comparative time-kill kinetics of niclosamide and Oxyclozanide against MRSA.
2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Wooseong Kim, Eleftherios MylonakisAbstract:The survival of MW2 in a broth culture treated with DMSO, niclosamide or Oxyclozanide at a concentration of 4 times the MIC. (MIC values: niclosamide 0.125 μg/ml, Oxyclozanide 0.5 μg/ml).
-
Chemical structure of the salicylanilide anthelmintic drugs niclosamide and Oxyclozanide.
2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Wooseong Kim, Eleftherios MylonakisAbstract:Chemical structure of the salicylanilide anthelmintic drugs niclosamide and Oxyclozanide.
-
Antibacterial activities of niclosamide and Oxyclozanide against staphylococcal strains.
2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Wooseong Kim, Eleftherios MylonakisAbstract:* is an S. epidermidis strain, rest are S. aureus strains.Antibacterial activities of niclosamide and Oxyclozanide against staphylococcal strains.
Rajmohan Rajamuthiah - One of the best experts on this subject based on the ideXlab platform.
-
Drugs to Combat Drug Resistant Staphylococcus aureus
2016Co-Authors: Repurposing Salicylanilide Anthelmintic, Beth Burgwyn Fuchs, Rajmohan Rajamuthiah, Annie L Conery, Wooseong Kim, Elamparithi Jayamani Bumsup KwonAbstract:Staphylococcus aureus is a Gram-positive bacterium that has become the leading cause of hospital acquired infections in the US. Repurposing Food and Drug Administration (FDA) approved drugs for antimicrobial therapy involves lower risks and costs compared to de novo development of novel antimicrobial agents. In this study, we examined the antimicrobi-al properties of two commercially available anthelmintic drugs. The FDA approved drug niclosamide and the veterinary drug Oxyclozanide displayed strong in vivo and in vitro activi-ty against methicillin resistant S. aureus (minimum inhibitory concentration (MIC): 0.125 and 0.5 μg/ml respectively; minimum effective concentration: 0.78 μg/ml for both drugs). The two drugs were also effective against another Gram-positive bacteria Enterococcus fae-cium (MIC 0.25 and 2 μg/ml respectively), but not against the Gram-negative species Kleb-siella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter aerogenes. The in vitro antimicrobial activity of niclosamide and Oxyclozanide were deter-mined against methicillin, vancomycin, linezolid or daptomycin resistant S. aureus clinical isolates, with MICs at 0.0625-0.5 and 0.125-2 μg/ml for niclosamide and Oxyclozanide re
-
repurposing salicylanilide anthelmintic drugs to combat drug resistant staphylococcus aureus
PLOS ONE, 2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Eleftherios MylonakisAbstract:Staphylococcus aureus is a Gram-positive bacterium that has become the leading cause of hospital acquired infections in the US. Repurposing Food and Drug Administration (FDA) approved drugs for antimicrobial therapy involves lower risks and costs compared to de novo development of novel antimicrobial agents. In this study, we examined the antimicrobial properties of two commercially available anthelmintic drugs. The FDA approved drug niclosamide and the veterinary drug Oxyclozanide displayed strong in vivo and in vitro activity against methicillin resistant S. aureus (minimum inhibitory concentration (MIC): 0.125 and 0.5 μg/ml respectively; minimum effective concentration: ≤ 0.78 μg/ml for both drugs). The two drugs were also effective against another Gram-positive bacteria Enterococcus faecium (MIC 0.25 and 2 μg/ml respectively), but not against the Gram-negative species Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter aerogenes. The in vitro antimicrobial activity of niclosamide and Oxyclozanide were determined against methicillin, vancomycin, linezolid or daptomycin resistant S. aureus clinical isolates, with MICs at 0.0625-0.5 and 0.125-2 μg/ml for niclosamide and Oxyclozanide respectively. A time-kill study demonstrated that niclosamide is bacteriostatic, whereas Oxyclozanide is bactericidal. Interestingly, Oxyclozanide permeabilized the bacterial membrane but neither of the anthelmintic drugs exhibited demonstrable toxicity to sheep erythrocytes. Oxyclozanide was non-toxic to HepG2 human liver carcinoma cells within the range of its in vitro MICs but niclosamide displayed toxicity even at low concentrations. These data show that the salicylanilide anthelmintic drugs niclosamide and Oxyclozanide are suitable candidates for mechanism of action studies and further clinical evaluation for treatment of staphylococcal infections.
-
Comparative time-kill kinetics of niclosamide and Oxyclozanide against MRSA.
2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Wooseong Kim, Eleftherios MylonakisAbstract:The survival of MW2 in a broth culture treated with DMSO, niclosamide or Oxyclozanide at a concentration of 4 times the MIC. (MIC values: niclosamide 0.125 μg/ml, Oxyclozanide 0.5 μg/ml).
-
Chemical structure of the salicylanilide anthelmintic drugs niclosamide and Oxyclozanide.
2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Wooseong Kim, Eleftherios MylonakisAbstract:Chemical structure of the salicylanilide anthelmintic drugs niclosamide and Oxyclozanide.
-
Antibacterial activities of niclosamide and Oxyclozanide against staphylococcal strains.
2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Wooseong Kim, Eleftherios MylonakisAbstract:* is an S. epidermidis strain, rest are S. aureus strains.Antibacterial activities of niclosamide and Oxyclozanide against staphylococcal strains.
Younes Smani - One of the best experts on this subject based on the ideXlab platform.
-
The anthelmintic Oxyclozanide restores the activity of colistin against colistin-resistant Gram-negative bacilli.
International journal of antimicrobial agents, 2019Co-Authors: Rafael Ayerbe-algaba, Jerónimo Pachón, María Luisa Gil-marqués, Andrea Miró-canturri, Raquel Parra-millán, María Eugenia Pachón-ibáñez, Manuel E. Jiménez-mejías, Younes SmaniAbstract:ABSTRACT Due to the significant increase in antimicrobial resistance in Gram-negative bacilli (GNB), development of non-antimicrobial therapeutic alternatives, which can be used together with the few and non-optimal available antimicrobial agents such as colistin, has become an urgent need. In this context, dysregulation of the bacterial cell wall could be a therapeutic adjuvant to the activity of colistin. The aim of this study was to analyse the activity of Oxyclozanide, an anthelmintic drug, in combination with colistin against colistin-susceptible (Col-S) and colistin-resistant (Col-R) GNB. Three Col-S reference strains and 13 clinical isolates (1 Col-S, 12 Col-R) of Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae were studied. Microdilution assays and time–kill curves were performed to examine the activity of Oxyclozanide in combination with colistin. The outer membrane protein (OMP) profile, membrane permeability and cell wall structure of Col-S and Col-R A. baumannii, P. aeruginosa and K. pneumoniae in the presence of Oxyclozanide were assessed by SDS-PAGE, fluorescence microscopy and transmission electron microscopy, respectively. Oxyclozanide in combination with colistin increased the activity of colistin against Col-S and Col-R A. baumannii, P. aeruginosa and K. pneumoniae. Time–kill curves showed synergistic activity between Oxyclozanide and colistin against these bacterial isolates. Moreover, Col-R A. baumannii, P. aeruginosa and K. pneumoniae in the presence of Oxyclozanide presented greater permeability and disruption of their cell wall than Col-S strains, without modification of their OMP profile. These data suggest that combination of Oxyclozanide and colistin may be a new alternative for the treatment of Col-R GNB infections.
-
Synergic effect of Oxyclozanide in combination with colistin against colistin-resistant and colistin-susceptible clinical strains of Klebsiella pneumoniae .
2016Co-Authors: Cristina Cerrada Romero, Rafael Ayerbe Algaba, R. Millan, Jerónimo Pachón, Younes SmaniAbstract:Motivation: Colistin is among the few antibiotics effective against Klebsiella pneumoniae clinical isolates. However, in the last few years, colistin-resistant K. pneumoniae have been isolated (1). Therefore, combination therapies between colistin and old drug effective against these isolates are required. The objective of this study is to study in vitro the activity of Oxyclozanide, an anthelmintic drug (2), in combination with colistin against colistin-susceptible (Col-S) and colistin-resistant K. pneumoniae. Methods: Col-R (KPc21) and Col-S (CECT 997) K. pneumonia strains were used. Checkerboard assay with colistin and Oxyclozanide to study the synergy between both drugs was performed. Time-kill assays using both strains at 6 log CFU/ml, colistin and Oxyclozanide were tested alone and in combination with sub-minimal inhibitory concentration (MIC) of colistin (0.25 µg/ml for CECT 997 strain and 16 µg/ml for KPc21 strain) and Oxyclozanide at 2 µg/ml. Analysis of KPc21 and CECT 997 strains cell walls in presence of 2 µg/ml Oxyclozanide during 24 h by transmission electron microscopy (TEM) was performed. Permeability assays and outer membrane proteins (OMPs) profile analysis by SDS-PAGE of both strains were performed. Results: Checkerboard assay showed a synergic effect between colistin and Oxyclozanide against the KPc21 strain (Fold change = 8), but not for CECT 997 strain (Fold change = 2). Time-kill assays showed a synergic effect between colistin and Oxyclozanide against the KPc21 strain (decreasing the bacterial growth by 3.24 log CFU/mL) at 24 h, but not against the CECT 997 strain whose bacterial growth was reduced by 0.45 log CFU/mL. Incubation with Oxyclozanide at 24 h did not cause change on the OMPs profile of both strains. Futhermore, the images from TEM showed that Oxyclozanide disrupted the bacterial cell envelope affecting its permeability. The membrane permeabilization assay confirmed these data, in which the Col-R strain had higher membrane permeability. Conclusions: From these in vitro data, we concluded that Oxyclozanide potentiates the bactericidal activity of colistin by disrupting the bacterial cell envelope. For this reason, Oxyclozanide would be a good adjuvant for colistin to treating the infections caused by K. pneumoniae.
Beth Burgwyn Fuchs - One of the best experts on this subject based on the ideXlab platform.
-
Drugs to Combat Drug Resistant Staphylococcus aureus
2016Co-Authors: Repurposing Salicylanilide Anthelmintic, Beth Burgwyn Fuchs, Rajmohan Rajamuthiah, Annie L Conery, Wooseong Kim, Elamparithi Jayamani Bumsup KwonAbstract:Staphylococcus aureus is a Gram-positive bacterium that has become the leading cause of hospital acquired infections in the US. Repurposing Food and Drug Administration (FDA) approved drugs for antimicrobial therapy involves lower risks and costs compared to de novo development of novel antimicrobial agents. In this study, we examined the antimicrobi-al properties of two commercially available anthelmintic drugs. The FDA approved drug niclosamide and the veterinary drug Oxyclozanide displayed strong in vivo and in vitro activi-ty against methicillin resistant S. aureus (minimum inhibitory concentration (MIC): 0.125 and 0.5 μg/ml respectively; minimum effective concentration: 0.78 μg/ml for both drugs). The two drugs were also effective against another Gram-positive bacteria Enterococcus fae-cium (MIC 0.25 and 2 μg/ml respectively), but not against the Gram-negative species Kleb-siella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter aerogenes. The in vitro antimicrobial activity of niclosamide and Oxyclozanide were deter-mined against methicillin, vancomycin, linezolid or daptomycin resistant S. aureus clinical isolates, with MICs at 0.0625-0.5 and 0.125-2 μg/ml for niclosamide and Oxyclozanide re
-
repurposing salicylanilide anthelmintic drugs to combat drug resistant staphylococcus aureus
PLOS ONE, 2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Eleftherios MylonakisAbstract:Staphylococcus aureus is a Gram-positive bacterium that has become the leading cause of hospital acquired infections in the US. Repurposing Food and Drug Administration (FDA) approved drugs for antimicrobial therapy involves lower risks and costs compared to de novo development of novel antimicrobial agents. In this study, we examined the antimicrobial properties of two commercially available anthelmintic drugs. The FDA approved drug niclosamide and the veterinary drug Oxyclozanide displayed strong in vivo and in vitro activity against methicillin resistant S. aureus (minimum inhibitory concentration (MIC): 0.125 and 0.5 μg/ml respectively; minimum effective concentration: ≤ 0.78 μg/ml for both drugs). The two drugs were also effective against another Gram-positive bacteria Enterococcus faecium (MIC 0.25 and 2 μg/ml respectively), but not against the Gram-negative species Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter aerogenes. The in vitro antimicrobial activity of niclosamide and Oxyclozanide were determined against methicillin, vancomycin, linezolid or daptomycin resistant S. aureus clinical isolates, with MICs at 0.0625-0.5 and 0.125-2 μg/ml for niclosamide and Oxyclozanide respectively. A time-kill study demonstrated that niclosamide is bacteriostatic, whereas Oxyclozanide is bactericidal. Interestingly, Oxyclozanide permeabilized the bacterial membrane but neither of the anthelmintic drugs exhibited demonstrable toxicity to sheep erythrocytes. Oxyclozanide was non-toxic to HepG2 human liver carcinoma cells within the range of its in vitro MICs but niclosamide displayed toxicity even at low concentrations. These data show that the salicylanilide anthelmintic drugs niclosamide and Oxyclozanide are suitable candidates for mechanism of action studies and further clinical evaluation for treatment of staphylococcal infections.
-
Comparative time-kill kinetics of niclosamide and Oxyclozanide against MRSA.
2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Wooseong Kim, Eleftherios MylonakisAbstract:The survival of MW2 in a broth culture treated with DMSO, niclosamide or Oxyclozanide at a concentration of 4 times the MIC. (MIC values: niclosamide 0.125 μg/ml, Oxyclozanide 0.5 μg/ml).
-
Chemical structure of the salicylanilide anthelmintic drugs niclosamide and Oxyclozanide.
2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Wooseong Kim, Eleftherios MylonakisAbstract:Chemical structure of the salicylanilide anthelmintic drugs niclosamide and Oxyclozanide.
-
Antibacterial activities of niclosamide and Oxyclozanide against staphylococcal strains.
2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Wooseong Kim, Eleftherios MylonakisAbstract:* is an S. epidermidis strain, rest are S. aureus strains.Antibacterial activities of niclosamide and Oxyclozanide against staphylococcal strains.
Annie L Conery - One of the best experts on this subject based on the ideXlab platform.
-
Drugs to Combat Drug Resistant Staphylococcus aureus
2016Co-Authors: Repurposing Salicylanilide Anthelmintic, Beth Burgwyn Fuchs, Rajmohan Rajamuthiah, Annie L Conery, Wooseong Kim, Elamparithi Jayamani Bumsup KwonAbstract:Staphylococcus aureus is a Gram-positive bacterium that has become the leading cause of hospital acquired infections in the US. Repurposing Food and Drug Administration (FDA) approved drugs for antimicrobial therapy involves lower risks and costs compared to de novo development of novel antimicrobial agents. In this study, we examined the antimicrobi-al properties of two commercially available anthelmintic drugs. The FDA approved drug niclosamide and the veterinary drug Oxyclozanide displayed strong in vivo and in vitro activi-ty against methicillin resistant S. aureus (minimum inhibitory concentration (MIC): 0.125 and 0.5 μg/ml respectively; minimum effective concentration: 0.78 μg/ml for both drugs). The two drugs were also effective against another Gram-positive bacteria Enterococcus fae-cium (MIC 0.25 and 2 μg/ml respectively), but not against the Gram-negative species Kleb-siella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter aerogenes. The in vitro antimicrobial activity of niclosamide and Oxyclozanide were deter-mined against methicillin, vancomycin, linezolid or daptomycin resistant S. aureus clinical isolates, with MICs at 0.0625-0.5 and 0.125-2 μg/ml for niclosamide and Oxyclozanide re
-
repurposing salicylanilide anthelmintic drugs to combat drug resistant staphylococcus aureus
PLOS ONE, 2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Eleftherios MylonakisAbstract:Staphylococcus aureus is a Gram-positive bacterium that has become the leading cause of hospital acquired infections in the US. Repurposing Food and Drug Administration (FDA) approved drugs for antimicrobial therapy involves lower risks and costs compared to de novo development of novel antimicrobial agents. In this study, we examined the antimicrobial properties of two commercially available anthelmintic drugs. The FDA approved drug niclosamide and the veterinary drug Oxyclozanide displayed strong in vivo and in vitro activity against methicillin resistant S. aureus (minimum inhibitory concentration (MIC): 0.125 and 0.5 μg/ml respectively; minimum effective concentration: ≤ 0.78 μg/ml for both drugs). The two drugs were also effective against another Gram-positive bacteria Enterococcus faecium (MIC 0.25 and 2 μg/ml respectively), but not against the Gram-negative species Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter aerogenes. The in vitro antimicrobial activity of niclosamide and Oxyclozanide were determined against methicillin, vancomycin, linezolid or daptomycin resistant S. aureus clinical isolates, with MICs at 0.0625-0.5 and 0.125-2 μg/ml for niclosamide and Oxyclozanide respectively. A time-kill study demonstrated that niclosamide is bacteriostatic, whereas Oxyclozanide is bactericidal. Interestingly, Oxyclozanide permeabilized the bacterial membrane but neither of the anthelmintic drugs exhibited demonstrable toxicity to sheep erythrocytes. Oxyclozanide was non-toxic to HepG2 human liver carcinoma cells within the range of its in vitro MICs but niclosamide displayed toxicity even at low concentrations. These data show that the salicylanilide anthelmintic drugs niclosamide and Oxyclozanide are suitable candidates for mechanism of action studies and further clinical evaluation for treatment of staphylococcal infections.
-
Comparative time-kill kinetics of niclosamide and Oxyclozanide against MRSA.
2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Wooseong Kim, Eleftherios MylonakisAbstract:The survival of MW2 in a broth culture treated with DMSO, niclosamide or Oxyclozanide at a concentration of 4 times the MIC. (MIC values: niclosamide 0.125 μg/ml, Oxyclozanide 0.5 μg/ml).
-
Chemical structure of the salicylanilide anthelmintic drugs niclosamide and Oxyclozanide.
2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Wooseong Kim, Eleftherios MylonakisAbstract:Chemical structure of the salicylanilide anthelmintic drugs niclosamide and Oxyclozanide.
-
Antibacterial activities of niclosamide and Oxyclozanide against staphylococcal strains.
2015Co-Authors: Rajmohan Rajamuthiah, Beth Burgwyn Fuchs, Annie L Conery, Elamparithi Jayamani, Bumsup Kwon, Frederick M Ausubel, Wooseong Kim, Eleftherios MylonakisAbstract:* is an S. epidermidis strain, rest are S. aureus strains.Antibacterial activities of niclosamide and Oxyclozanide against staphylococcal strains.
